Research programme: RNA interference-based therapeutics - Abbott/Dharmacon
Latest Information Update: 25 Jan 2013
At a glance
- Originator Abbott Laboratories; Dharmacon
- Mechanism of Action RNA interference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 06 Jul 2006 Early research in Cancer in USA (unspecified route)